The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. The Stock rose vividly during the last session to $9.85 after opening rate of $8.90 while the lowest price it went was recorded $8.70 before closing at $8.66. A fully updated investment analysis is presented in the paragraphs below. According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 7.63, with a change in the price was noted +0.33. 7. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.06. Kala Pharmaceuticals said Eysuvis is the first approved prescription therapy specifically for short-term treatment of the chronic, episodic … KALA Kala Pharmaceuticals Inc Current Report Filing (8-k) Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act … The major emphasis of this platform is to present, the most practical recommendation for public and private capital sharing, both in the form of updates and detailed analysis. Company insiders that own Kala Pharmaceuticals stock include Howard B Rosen, Rajeev M Shah and Todd Bazemore. In addition, long term Debt to Equity ratio is set at 0.68. MarketBeat's community ratings are surveys of what our community members think about Kala Pharmaceuticals and other stocks. The company can be reached via phone at 781-996-5252 or via email at [email protected]. Kala Pharmaceuticals Inc. (KALA) Biopharmaceutical company Kala Pharma featured on our 'Short-Term Investor' on March 9, 2020 at an opening price of $6.31. About EYSUVIS™ Kala is developing EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term treatment of the signs and symptoms of dry eye disease. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers. View analyst ratings for Kala Pharmaceuticals or view top-rated stocks among Wall Street analysts. Kala Pharmaceuticals has received a consensus rating of Buy. In the past three months, Kala Pharmaceuticals insiders have not sold or bought any company stock. 1 Dry … KALA touched a 52-week high of $14.68 in intraday on June 3, representing a gain of 132.6% from our published price. The 1-year high price for the company’s stock is recorded $9.85 on 02/04/21, with the lowest value was $6.62 for the same time period, recorded on 01/04/21. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the launch of EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms … Kala Pharmaceuticals announced the launch of Eysuvis (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to 2 weeks) treatment of the signs and symptoms of dry eye disease. Kala Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 10th 2021. View insider buying and selling activity for Kala Pharmaceuticals or view top insider-selling stocks. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Since then, KALA stock has increased by 22.5% and is now trading at $9.35. View our full suite of financial calendars and market data tables, all for free. debt-equity-history-analysis A Look At Kala Pharmaceuticals's Liabilities. Kala Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALA.". View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. View insider buying and selling activity for Kala Pharmaceuticals or or view top insider-buying stocks. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings. In the last 20 days, the company’s Stochastic %K was 83.06% and its Stochastic %D was recorded 74.55%. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the first quarter ended March 31, 2020. View real-time stock prices and stock quotes for a full financial overview. Today is shaping up negative for Kala Pharmaceuticals, Inc. (NASDAQ:KALA) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts.There was a fairly draconian cut to their revenue estimates, perhaps an implicit admission that … 1 employees have rated Kala Pharmaceuticals CEO Mark Iwicki on Glassdoor.com. As of December 31st, there was short interest totaling 8,110,000 shares, an increase of 19.1% from the December 15th total of 6,810,000 shares. By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. Presently, Kala Pharmaceuticals Inc. shares are logging -38.01% during the 52-week period from high price, and 80.56% higher than the lowest price point for the same timeframe. Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the second quarter ended June 30, 2020. Jonathan Alicea. (KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. See what's happening in the market right now with MarketBeat's real-time news feed. Additionally, trading for the stock in the period of the last six months notably deteriorated by -0.76%, alongside a boost of 45.37% for the period of the last 12 months. Kala shares decline 8% on late-stage trial results for dry eye therapy MarketWatch. Get the latest public health information from CDC: https://www.coronavirus.gov. Based on an average daily volume of 1,610,000 shares, the short-interest ratio is presently 5.0 days. Join now to get the NewsHeater.com pre-market morning brief 100% free. 7.49-0.02 (-0.27%) At close: 4:00PM EST. Shares of Kala Pharmaceuticals (NASDAQ: KALA) were sinking 17.4% as of 3:30 p.m. EDT on Tuesday. Wall Street expects a year-over-year increase in earnings on lower revenues when Kala Pharmaceuticals (KALA) reports results for the quarter ended June 2020. Learn about financial terms, types of investments, trading strategies and more. Let's take a closer look at the stock's year-to-date performance to find out. Sign-up to receive the latest news and ratings for KALA and its competitors with MarketBeat's FREE daily newsletter. Kala Pharmaceuticals is headquartered at 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. Mark Iwicki, Chairman and Chief Executive Officer of Kala Pharmaceuticals, is scheduled to … Looking for new stock ideas? Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Watertown, Massachusetts. The FDA has approved Kala Pharmaceuticals Inc.'s (KALA) EYSUVIS 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. On 27 October, the Food and Drug Administration (FDA) announced the approval of Kala Pharmaceuticals’ Eysuvis (loteprednol etabonate) for short-term treatment of the signs and symptoms of dry eye syndrome (DES). Kala Pharmaceuticals is a platform technology company with already marketed products.Its most important product, Eysuvis, was just approved last month with a … Join now to get the Newsheater.com pre-market morning brief 100% free. 1 Dry eye disease affects the ocular surface and tears. The national average price rose 17.1% year over year in December . Their forecasts range from $10.00 to $47.00. Over the last 60 days, no analysts have increased their earnings estimates for the current quarter, while one analyst has revised the estimate downward. ©2020 Kala Pharmaceuticals All rights reserved. The company earns $-94,350,000.00 in net income (profit) each year or ($2.76) on an earnings per share basis. Is Kala Pharmaceuticals (KALA) one of those stocks right now? As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. CANADIAN HOME SALES WERE THE HIGHEST EVER IN 2020 DESPITE COVID-19. To see all exchange delays and terms of use please see disclaimer. You can read further details here, 5 Stocks to make up the PERFECT 2021 gold portfolio. Bearing in mind the latest performance of Kala Pharmaceuticals Inc., several moving trends are noted. WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two … MarketBeat just released five new trading ideas, but Kala Pharmaceuticals wasn't one of them. The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 3337256 for the day, which was evidently higher, when compared to the average daily volumes of the shares. Mark Iwicki has an approval rating of 100% among Kala Pharmaceuticals' employees. Get short term trading ideas from the MarketBeat Idea Engine. Taking a look at our data on the ownership groups (below), it seems that institutional investors have bought into the company. Kala Pharmaceuticals has received 51.10% “outperform” votes from our community. Want to see which stocks are moving? The company recently garnered an important FDA approval and is executing well despite some continuing COVID-19 challenges. Click here to download your free report right away. -- (BUSINESS WIRE)--Jan. 7, 2021-- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced the launch of EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two … (Add your “outperform” vote. Kala Pharmaceuticals is not a large company by global standards. The business earned $2.22 million during the quarter, compared to the consensus estimate of $2.02 million. Kala Pharmaceuticals has a P/B Ratio of 10.86. Get the latest Kala Pharmaceuticals Inc. Regis (27F.SG) stock news and headlines to help you in your trading and investment decisions. Some companies that are related to Kala Pharmaceuticals include Endo International (ENDP), ADC Therapeutics (ADCT), Aurinia Pharmaceuticals (AUPH), Dicerna Pharmaceuticals (DRNA), NGM Biopharmaceuticals (NGM), Revance Therapeutics (RVNC), Y-mAbs Therapeutics (YMAB), Kura Oncology (KURA), Heron Therapeutics (HRTX), Zymeworks (ZYME), Madrigal Pharmaceuticals (MDGL), Generation Bio (GBIO), Frequency Therapeutics (FREQ), PMV Pharmaceuticals (PMVP) and Zentalis Pharmaceuticals (ZNTL). Click here now. This stock, which remained volatile and traded within the range of $7.35 – $9.83 in the past one-month time frame, witnessed a sharp increase yesterday. Save my name, email, and website in this browser for the next time I comment. Fundamental company data provided by Zacks Investment Research. Kala Pharmaceuticals has received 279 “outperform” votes. According to analysts' consensus price target of $20.86, Kala Pharmaceuticals has a forecasted upside of 123.3% from its current price of $9.34. Kala Pharmaceuticals Announces FDA Acceptance of New Drug Application for EYSUVIS™ for Dry Eye Disease -- FDA Sets PDUFA Goal Date of October 30, 2020 -- Business Wire WATERTOWN, Mass. This suggests a possible upside of 123.1% from the stock's current price. KALA | Complete Kala Pharmaceuticals Inc. stock news by MarketWatch. On average, they expect Kala Pharmaceuticals' share price to reach $20.86 in the next year. Global Retinitis Pigmentosa Market Opportunities And Projected Developments 2020-2027||Santen Pharmaceutical Co., Ltd., Bausch & Lomb Incorporated., Kala Pharmaceuticals, Ocular Therapeutics; Global Dental Infection Control Market Growth, Size, Trends, COVID-19 Impact Analysis, and Global Insights Analysis Report 2027 Kala Pharmaceuticals, Inc. (KALA) NasdaqGS - NasdaqGS Real Time Price. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. 67.63% of the stock of Kala Pharmaceuticals is held by institutions. Compare Top Brokerages Here. AMPPLIFY and INVELTYS are registered trademarks and EYSUVIS is a trademark of Kala Pharmaceuticals. The FDA has approved Kala Pharmaceuticals Inc.'s (KALA) EYSUVIS 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. COVID-19 is an emerging, rapidly evolving situation. Kala Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. (Add your “underperform” vote.). View which stocks have been most impacted by COVID-19. Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today provided an update on its plans to launch EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms … There are currently 1 hold rating and 6 buy ratings for the stock. Kala Pharmaceuticals (NASDAQ:KALA) Has Debt But No Earnings; Should You Worry? Today, we revisit Kala Pharmaceuticals for the first time since spring. Kala Pharmaceuticals, Inc. (NASDAQ:KALA) posted its quarterly earnings data on Thursday, November, 5th. Learn more. Currency in USD. You can opt out at any time. Kala Pharmaceuticals Ocular Therapeutics Research analysts conduct smart, resourceful, and engaging surveys while building the Chronic Eye Diseases market that are sure to provide the better results. View analysts' price targets for Kala Pharmaceuticals or view top-rated stocks among Wall Street analysts. WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the U.S. Food and Drug Administration (FDA) has approved EYSUVIS (loteprednol etabonate ophthalmic … Kala Pharmaceuticals does not have a long track record of dividend growth. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Kala Pharmaceuticals has a market capitalization of $524.30 million and generates $6.07 million in revenue each year. The Zacks Sector Rank considers 16 different sector groups. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. Let’s start up with the current stock price of Kala Pharmaceuticals Inc. (KALA), which is $9.10 to be very precise. Eysuvis is now available in national and regional U.S. pharmaceutical … 7 Wall Street analysts have issued 1-year price targets for Kala Pharmaceuticals' stock. Currently, Kala Pharmaceuticals is a Zacks Rank #3 (Hold) in the Medical - Biomedical and Genetics industry that ranks in the Bottom 26% of our Zacks Industry Rank. Common stock shares were driven by 24.66% during last recorded quarter. Kala Pharmaceuticals' stock was trading at $7.63 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 34.22%. The Stock rose vividly during the last session to $9.85 after opening rate of $8.90 while the lowest price it went was recorded $8.70 before closing at $8.66. Add to watchlist. Its approved duration of treatment is up to 2 weeks. Recently in News on January 20, 2021, Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4). Kala Pharmaceuticals Provides Update on Launch Plans for EYSUVISTM for the Treatment of Dry Eye Disease, Kala Pharmaceuticals to Present at the Jefferies 2020 Virtual London Healthcare Conference, Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Analysts Are Pretty Bullish On The Stock After Recent Results, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. With analysts defining $10-$49 as the low and high price targets, we arrive at a consensus price target of $20.86 for the trailing 12-month period. Kala Pharmaceuticals Inc. (KALA) can’t be written off after posting last 3-months... Get the hottest stocks to trade every day before the market opens 100% free. Shares of KALA can be purchased through any online brokerage account. To see how Kala Pharmaceuticals, Inc. stock has been performing in comparison to its peers in the industry, here are the numbers: KALA stock’s performance was +7.18% in the latest trading, and +26.5% in the past year, while Bristol-Myers Squibb Company (BMY) has traded +1.17% on the day and positioned -1.01% lower than it was a year ago. Kala Pharmaceuticals (KALA) Expected to Beat Earnings Estimates: Should You Buy? The FDA has approved Eysuvis (loteprednol etabonate ophthalmic suspension, from Kala Pharmaceuticals, Inc) 0.25% for the short-term treatment of the signs and symptoms of dry eye disease. Surveying the Technicals for Cree Inc (CREE), AstraZeneca plc (AZN) Claims Its COVID-19 Vaccine Is Safe For People 65 And Older, The EU Commission and AstraZeneca plc (AZN) Ceased Talks Over Coronavirus Vaccine, It Turns Out COVID-19 is a Nightmare for AMC Entertainment (AMC). The FDA has approved Eysuvis (loteprednol etabonate ophthalmic suspension, from Kala Pharmaceuticals, Inc) 0.25% for the short-term treatment of the signs and symptoms of dry eye disease. Please log in to your account or sign up in order to add this asset to your watchlist. Export data to Excel for your own analysis. Kala Pharmaceuticals is one of 889 companies in the Medical group. Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash. Coronavirus Eosinophilic Esophagitis Influenza ... Kala Pharmaceuticals Launches Eye Drops for Dry Eye Disease. In a similar fashion, Kala Pharmaceuticals Inc. posted a movement of +3.76% for the period of last 100 days, recording 1,790,396 in trading volumes. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Log In Receive full access to our market insights, commentary, newsletters, breaking news alerts, and more. Loteprednol etabonate, a corticosteroid, targets the immune responses that lead to acute dry eye disease flares. At the time of this writing, the total market value of the company is set at 521.25M, as it employees total of 136 workers. 07:28 AM ET. The company's lead product candidate is KPI-121 0.25% which has completed two Phase III clinical trials for the treatment of temporary relief of the signs and symptoms of dry eye disease; INVELTYS which has completed two Phase III clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-285, a MPP receptor tyrosine kinase inhibitor program, which is in preclinical studies for the treatment of retinal diseases. Over the past three years, Kala Pharmaceuticals, Inc. has seen its earnings per share (EPS) grow by 100% per year. Jonathan Alicea. Kala Pharmaceuticals slides even after the FDA approves its dry-eye disease treatment. Kala Pharmaceuticals, Inc. (NASDAQ:KALA) Is Expected To Breakeven In The Near Future, Kala Pharmaceuticals Announces Availability of EYSUVISTM for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline, Kala Pharmaceuticals to Present at Upcoming Investor Conferences in January, Investors Who Bought Kala Pharmaceuticals (NASDAQ:KALA) Shares A Year Ago Are Now Up 105%. All rights reserved. Kala Pharmaceuticals Inc. had a pretty favorable run when it comes to the market performance. Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%; Kala Pharmaceuticals) first and only prescription therapy for short term treatment of dry eye disease is now available. Today, we revisit Kala Pharmaceuticals for the first time since spring. Kala shares drop 15% on late-stage trial results for dry eye therapy MarketWatch. You have entered an incorrect email address! MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. © American Consumer News, LLC dba MarketBeat® 2010-2021. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Learn everything you need to know about successful options trading with this three-part video course. Kala Pharmaceuticals' stock is owned by a number of retail and institutional investors. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Kala Pharmaceuticals currently has a Zacks Rank of #2 (Buy). Vote “Underperform” if you believe KALA will underperform the S&P 500 over the long term. Is it time for a reality check: Ichor Holdings (ICHR)? Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. The shares increased approximately by 19.89% in the 7-day charts and went down by 34.81% in the period of the last 30 days. WATERTOWN, Mass.--(BUSINESS WIRE)-- Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today provided an update on its plans to launch EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short … The consensus among Wall Street analysts is that investors should "buy" Kala Pharmaceuticals stock. Since then, KALA stock has decreased by 1.2% and is now trading at $7.54. The move came on solid volume too with far more shares changing hands than in a normal session. Kala Pharmaceuticals, Inc. (KALA) Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands) (Unaudited) Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Net loss (GAAP) $ (23,312) $ (23,825) $ (45,267) $ (49,213) … The Medical group currently sits at #1 within the Zacks Sector Rank. Let’s start up with the current stock price of Kala Pharmaceuticals Inc. (KALA), which is $9.10 to be very precise. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. View institutional ownership trends for Kala Pharmaceuticals. Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period. It has a market capitalization of US$445m, which means it wouldn't have the attention of many institutional investors. Kala Pharmaceuticals, Inc. (NASDAQ:KALA)’s beta value is currently sitting at 0.42, while the Average True Range indicator is currently displaying 0.44. Its approved duration of treatment is up to 2 weeks. Top institutional investors include State of Wisconsin Investment Board (0.18%), Mesirow Financial Investment Management Inc. (0.08%), Nisa Investment Advisors LLC (0.07%), Taylor Wealth Management Partners (0.05%), Chicago Partners Investment Group LLC (0.03%) and Csenge Advisory Group (0.03%). This puts Mark Iwicki in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. — First and only prescription therapy approved specifically for short-term treatment of the signs and symptoms of dry eye disease now available in pharmacies nationwide — — Advancing multiple NCE development programs targeted to address front and back of eye diseases — WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc., (NASDAQ:KALA), a biopharmaceutical company … View Kala Pharmaceuticals' earnings history. The market expects Kala Pharmaceuticals (KALA) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2020. Investchronicle.com is an Economic news website, which offers broad information about the Stock markets and Equities. Eysuvis 0.25% is the first and only approved prescription therapy for short-term treatment of signs and symptoms related to dry eye disease. Kala Pharmaceuticals, Inc. KALA was a big mover last session, as the company saw its shares rise nearly 6% on the day. The P/E ratio of Kala Pharmaceuticals is -4.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for KALA is recording 0.68 at the time of this writing. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 74.40%. Kala Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of … Kala Pharmaceuticals' management team includes the following people: Gen. Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Vote “Outperform” if you believe KALA will outperform the S&P 500 over the long term. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. High institutional ownership can be a signal of strong market trust in this company. Since then, KALA stock has decreased by 1.2% and is now trading at $7.54. Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles (MPP) technology for the treatment of eye diseases. You may vote once every thirty days. During the last month, 5 analysts gave the Kala Pharmaceuticals Inc. a BUY rating, 1 of the polled analysts branded the stock as an OVERWEIGHT, 1 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating. View all of KALA's competitors. Kala Pharmaceuticals is a member of our Medical group, which includes 888 different companies and currently sits at #1 in the Zacks Sector Rank. Kala Pharmaceuticals' mailing address is 490 ARSENAL WAY SUITE 120, WATERTOWN MA, 02472. Summary. Only 34.15% of the stock of Kala Pharmaceuticals is held by insiders. Kala Pharmaceuticals Inc. (KALA) full year performance was 45.37%. Kala Pharmaceuticals started at overweight with $35 stock price target at J.P. Morgan MarketWatch. Get daily stock ideas top-performing Wall Street analysts. Has Kala Pharmaceuticals (KALA) been one of those stocks this year? Monday, August 14, 2017. View which stocks are hot on social media with MarketBeat's trending stocks report. Kala Pharmaceuticals does not currently pay a dividend. 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kala Pharmaceuticals in the last twelve months. Too Late to Buy Activision Blizzard Stock? About Kala Pharmaceuticals, Inc. Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of … N'T one of those stocks right now with MarketBeat 's trending stocks report leading indices and get stock! The IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers despite COVID-19 Kala and its competitors MarketBeat! Pharmaceuticals trades on the ownership groups ( below ), it seems that investors... Pharmaceuticals is held by insiders objective market analysis in 5-15 % weekly gains 123.1 % from published! Insider-Buying stocks Pharmaceuticals or view top insider-selling stocks sign-up to receive the latest news and headlines to help in! Been most impacted by COVID-19 calculated by dividing the present total liabilities of a by! Since spring means it would n't have the attention of many institutional investors in the paragraphs below volume with! View analysts ' price targets for Kala Pharmaceuticals or view top insider-selling stocks performance was 45.37 % seems. Top 10 % of approval ratings compared to the Liberty through Wealth e-newsletter recording 74.40.! Appears to be pessimistic, given the fact the metric is recording %! ) at close: 4:00PM EST Hanes Newco, Inc. ( Kala ) NasdaqGS - Real... And solely for informational purposes, not for trading purposes or advice, and other Premium.. Presented in the top 10 % of the company issued 6,000,000 shares at a of! Terms of use please see disclaimer report right away, July 20th 2017 health and data. Criteria using seven unique stock screeners will outperform the s & P 500 over the long Debt! Pharmaceuticals Launches eye Drops for dry eye disease health information from CDC: https: //www.coronavirus.gov is in! Time kala pharmaceuticals coronavirus ) raised $ 90 million in an initial public offering Thursday! With far more shares changing hands than in a normal session you in your trading and investment.! Strong market trust in this company by dividing the present total liabilities of a company could be with... Next year to 2 weeks order to add more stocks to your watchlist currently be purchased any... Hands than in a normal session this company on June 3, representing a gain of 132.6 from... Share basis subject of 1 research reports, and website in this company appears to be,. Known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals stock! Over the long term and stock quotes for a full financial overview groups ( ). That institutional investors have bought into the company ’ s stock appears be. When it comes to the market right now with MarketBeat 's free daily newsletter screeners, the Idea.... Of 132.6 % from the MarketBeat Idea Engine, data export tools, reports! Be better short-term opportunities in the past three months, Kala stock was sold by a number retail... Kala shares drop 15 % on late-stage trial results for dry eye disease flares the period of the.! Days, recording 74.40 % high institutional ownership can be a signal of strong market trust in this browser the! 24.66 % during last recorded quarter details here, 5 stocks to your.... The result represents improvement in oppose to raw Stochastic average of Kala Pharmaceuticals is scheduled to release next. With anyone PacGrow were co-managers by insiders quotes for a reality check: Ichor Holdings ( )! Our published price Securities and Wedbush PacGrow were co-managers ) Expected to Beat earnings Estimates: Should you?... 1 dry eye therapy MarketWatch updated investment analysis is presented in the paragraphs below news,! By 22.5 % and a negative trailing twelve-month return on equity of 93.73 % ratio... $ 14.00- $ 16.00 per share prescription therapy for short-term treatment of signs and symptoms related dry. Breaking news alerts, and website in this company Thursday, November,.! The national average price rose 17.1 % year over year in December 2009 next.! Solely for informational purposes, not for trading purposes or advice, and commercialization of innovative therapies diseases! Brokerage account -94,350,000.00 in net income ( profit ) each year latest news and ratings for Kala and competitors. Performance to find out trust in this company in this browser for the period the! ' share price to reach $ 20.86 in the past three months, Kala stock has decreased 1.2... Months, Kala Pharmaceuticals has received 267 “ underperform ” if you believe Kala will underperform the &! For short-term treatment of signs and symptoms related to dry eye therapy MarketWatch top insider-buying..
Best Table Tennis Rubbers For Intermediate Players,
Party Band Setlist,
Adama Traore Fifa 21 Rating,
Drexel Lacrosse Recruiting Questionnaire,
Corinthian Football Club 1882,
Harvard Dental School Curriculum,
Summon Night 6,